UK-240455

Research use only, not for human use.

UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improvements in motor function in Parkinson's disease models, making it a potential candidate for Parkinson's disease treatment.

UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist.

——

UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist. Following i.v. administration of UK-240455 to male rats, UK-240455 has a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 decreases with an apparent half-life of 0.4 h. Analysis of urine (0 to 24 h) for unchanged UK-240455 indicates that 57% of the dose administered is excreted unchanged in the urine. The urinary clearance of UK-240455 in the rat is therefore 7 mL/min/kg. Following oral administration of UK-240455 to male rats, the apparent elimination half-life of UK-240455 from plasma following oral administration is 1.6 h.

——

Membrane Transporter/Ion Channel

iGluR

iGluR | NMDAR

——

——

178908-09-3

368.19

C11H11Cl2N3O5S

>98% (HPLC)

——

N(CCO)(S(C)(=O)=O)C1=C2C(=CC(Cl)=C1Cl)NC(=O)C(=O)N2

——

(-20℃)

With Ice Pack

≥ 2 years